3017 Terasaki Life Sciences Building
610 Charles E. Young Drive East
Los Angeles, CA 90095
Recent Publications
Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells
Med
Exploriong the alternative approach of using allogenic CAR-engineered invariant natural killer T (AlloCAR-NKT) cells to not only combat chemo resistant ovarian cancer tumors but also remodel the tumor micro environment.
Tumor extracellular vesicle surface Protein-mRNA integration assay for early detection of epithelial ovarian cancer
eBioMedicine
Tumour-derived extracellular vesicles (EVs) are a promising potential biomarker for epithelial ovarian cancer. Here we deveopled a Surface Protein-mRNA Integration (SPRI) Assay for early detection.
A case series of four patients with recurrent ovarian granulosa cell tumors treated with CDK4/6 inhibitors and estrogen blockade in a pilot study
European Journal of Gynaecological Oncology
There is currently no established optimal treatment for advanced or recurrent granulosa cell tumors (GCTs), making management challenging. Given the success of CDK4/6 inhibitors in hormone receptor-positive breast cancer, we explored their use in GCTs.
Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays
STAR Protocols
Protocol to characterize primary ovarian cancer patient samples and a detalied design and evaluation of various cell-based immunotherapies aimed at targeting primary tumors and the tumor microenvironment through in vitro killing assays.
Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity
Cancer Immunology, Immunotherapy
We extended our previous observations with other tumor models to study seven ovarian tumor cell lines-OVCAR3, OVCAR4, OVCAR8, SKOV3, Kuramochi, OAW28, and CaOV3. We found that NK cells targeted and killed poorly differentiated OVCAR8 and CAOV3; these two tumor lines express lower MHC-class I and higher CD44 surface receptors. OVCAR3 and OVCAR4 were more resistant to NK cell-mediated cytotoxicity, and SKOV3, Kuramochi and OAW28 had intermediate sensitivity to NK cell-mediated cytotoxicity, likely representing well-differentiated and moderately differentiated ovarian tumor cell lines, respectively.
cfTrack: Exome-wide mutation analysis of cell-free DNA to simultaneously monitor the full spectrum of cancer treatment outcomes: MRD, recurrence, and evolution
Clinical Cancer Research
Cell-free DNA (cfDNA) offers a non-invasive approach to monitor cancer. Here we develop a method using whole-exome sequencing (WES) of cfDNA for simultaneously monitoring the full spectrum of cancer treatment outcomes, including MRD, recurrence, evolution, and second primary cancers.
Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers
International Journal of Oncology
Patients diagnosed with epithelial ovarian cancers (EOCs) often suffer from disease relapse associated with the emergence of resistance to standard platinum‑based chemotherapy. Treatment of patients with chemo‑resistant disease remains a clinical challenge. One mechanism of chemoresistance includes ...
SUPPORT RESEARCH
Donate
Every donation is gratefully accepted and will be put to use on the work of the lab. There are many ways to donate, and all make a difference. If you share our passion for finding better treatments for women’s cancer, please consider giving hope by donating to this important cause.